BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Simmons B, Wentzel H, Mobarak S, Eslami G, Sadeghi A, Ali Asgari A, Abbaspour Kasgari H, Tirgar Fakheri H, Merat S, Hill A. Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis. J Antimicrob Chemother. 2021;76:286-291. [PMID: 33063117 DOI: 10.1093/jac/dkaa418] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Butt AA, Yan P, Chotani RA, Shaikh OS. Mortality is not increased in SARS-CoV-2 infected persons with hepatitis C virus infection. Liver Int 2021;41:1824-31. [PMID: 33534931 DOI: 10.1111/liv.14804] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
2 Drożdżal S, Rosik J, Lechowicz K, Machaj F, Szostak B, Przybyciński J, Lorzadeh S, Kotfis K, Ghavami S, Łos MJ. An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment. Drug Resist Updat 2021;:100794. [PMID: 34991982 DOI: 10.1016/j.drup.2021.100794] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Chen C, Weng T, Chen Y, Kao JH, Chao C. Clinical efficacy of sofosbuvir/daclatasvir in patients with COVID-19: a systematic review and meta-analysis of randomized trials. Expert Review of Clinical Pharmacology. [DOI: 10.1080/17512433.2022.2103539] [Reference Citation Analysis]
4 Tam NM, Pham MQ, Ha NX, Nam PC, Phung HTT. Computational estimation of potential inhibitors from known drugs against the main protease of SARS-CoV-2. RSC Adv 2021;11:17478-86. [DOI: 10.1039/d1ra02529e] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
5 Tao K, Tzou PL, Nouhin J, Bonilla H, Jagannathan P, Shafer RW. SARS-CoV-2 Antiviral Therapy. Clin Microbiol Rev 2021;:e0010921. [PMID: 34319150 DOI: 10.1128/CMR.00109-21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Wang J, Wagner AL, Chen Y, Jaime E, Hu X, Wu S, Lu Y, Ruan Y, Pan SW. Would COVID-19 vaccination willingness increase if mobile technologies prohibit unvaccinated individuals from public spaces? A nationwide discrete choice experiment from China. Vaccine 2021:S0264-410X(21)01340-2. [PMID: 34742594 DOI: 10.1016/j.vaccine.2021.10.020] [Reference Citation Analysis]
7 Messina V, Nevola R, Izzi A, De Lucia Sposito P, Marrone A, Rega R, Fusco R, Lumino P, Rinaldi L, Gaglione P, Simeone F, Sasso FC, Maggi P, Adinolfi LE. Efficacy and safety of the sofosbuvir/velpatasvir combination for the treatment of patients with early mild to moderate COVID-19. Sci Rep 2022;12:5771. [PMID: 35388092 DOI: 10.1038/s41598-022-09741-5] [Reference Citation Analysis]
8 Khalili H, Nourian A, Ahmadinejad Z, Emadi Kouchak H, Jafari S, Dehghan Manshadi SA, Rasolinejad M, Kebriaeezadeh A. Efficacy and safety of sofosbuvir/ ledipasvir in treatment of patients with COVID-19; A randomized clinical trial. Acta Biomed 2020;91:e2020102. [PMID: 33525212 DOI: 10.23750/abm.v91i4.10877] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
9 Mobarak S, Salasi M, Hormati A, Khodadadi J, Ziaee M, Abedi F, Ebrahimzadeh A, Azarkar Z, Mansour-Ghanaei F, Joukar F, Yeganeh S, Yaghubi Kalurazi T, Naghipour M, Mehrabi Z, Bahadori AR, Yaghoubi S, Moslemi R, Abbaspour Kasgari H, Fakheri H, Moghimi M, Shabani AM, Nekoukar Z, Babamahmoodi F, Davoudi Badabi AR, Davoodi L, Hassaniazad M, Barahimi E, Tousi A, Sadeghi A, Hosamirudsari H, Ali Asgari A, Abdollahi M, Anushiravani A, Shabani M, Shokouhi S, Khajavirad N, Salehi M, Dehghan Manshadi SA, Mousavi H, Zolfaghari F, Azimi E, Zeinali A, Akbarpour E, Merat D, Eslami G, Mousaviasl S, Sayar S, Radmanesh E, Ebrahimzadeh M, Arizavi Z, Jelvay S, Salmanzadeh S, Esmaeilian H, Mobarak M, Karimi J, Poormontaseri Z, Hasooni Bahrini N, Bonyadi A, Dehghani F, Mirzaei H, Noori Jangi M, Pourmasoomi H, Rezaie Keikhaie L, Afshari M, Nateghi Baygi A, Nateghi Baygi H, Levi J, McCann K, Wentzel H, Simmons B, Hill A, Merat S. Evaluation of the effect of sofosbuvir and daclatasvir in hospitalized COVID-19 patients: a randomized double-blind clinical trial (DISCOVER). J Antimicrob Chemother 2021:dkab433. [PMID: 34849957 DOI: 10.1093/jac/dkab433] [Reference Citation Analysis]
10 Spearman CW, Aghemo A, Valenti L, Sonderup MW. COVID-19 and the liver: A 2021 update. Liver Int 2021;41:1988-98. [PMID: 34152690 DOI: 10.1111/liv.14984] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Kow CS, Javed A, Ramachandram D, Hasan SS. Clinical outcomes of sofosbuvir-based antivirals in patients with COVID-19: a systematic review and meta-analysis of randomized trials. Expert Rev Anti Infect Ther 2021;:1-9. [PMID: 34719324 DOI: 10.1080/14787210.2022.2000861] [Reference Citation Analysis]
12 Gil Martínez V, Avedillo Salas A, Santander Ballestín S. Antiviral Therapeutic Approaches for SARS-CoV-2 Infection: A Systematic Review. Pharmaceuticals (Basel) 2021;14:736. [PMID: 34451833 DOI: 10.3390/ph14080736] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
13 Bitaraf E, Ahmadi SAY, Gandomi-Mohammadabadi A, Noorani Mejareh Z, Abdollahi B, Balasi J, Moodi F, Hemmati N, Kabir A. Effects of Immune System-Related Medications on COVID-19 Outcome in a Cohort of Iranian Patients: Preliminary Report of a Data Mining Study. J Immunol Res 2021;2021:9934134. [PMID: 34307694 DOI: 10.1155/2021/9934134] [Reference Citation Analysis]
14 Dowarah J, Marak BN, Yadav UCS, Singh VP. Potential drug development and therapeutic approaches for clinical intervention in COVID-19. Bioorg Chem 2021;114:105016. [PMID: 34144277 DOI: 10.1016/j.bioorg.2021.105016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Spera AM. Are nucleotide inhibitors, already used for treating hepatitis C virus infection, a potential option for the treatment of COVID-19 compared with standard of care? A literature review. World J Virol 2021; 10(2): 53-61 [PMID: 33816150 DOI: 10.5501/wjv.v10.i2.53] [Reference Citation Analysis]